Keyword search (4,163 papers available)

"Sonenberg N" Authored Publications:

Title Authors PubMed ID
1 Alzheimer model chip with microglia BV2 cells Yazdanpanah Moghadam E; Sonenberg N; Packirisamy M; 40623989
ENCS
2 Microfluidic Wound-Healing Assay for Comparative Study on Fluid Dynamic, Chemical and Mechanical Wounding on Microglia BV2 Migration Yazdanpanah Moghadam E; Sonenberg N; Packirisamy M; 39203655
ENCS
3 Microfluidic Wound-Healing Assay for ECM and Microenvironment Properties on Microglia BV2 Cells Migration Yazdanpanah Moghadam E; Sonenberg N; Packirisamy M; 36832056
ENCS
4 Lab-On-A-Chip for the Development of Pro-/Anti-Angiogenic Nanomedicines to Treat Brain Diseases. Subramaniyan Parimalam S, Badilescu S, Sonenberg N, Bhat R, Packirisamy M 31817343
ENCS
5 The eIF2α Kinase GCN2 Modulates Period and Rhythmicity of the Circadian Clock by Translational Control of Atf4. Pathak SS, Liu D, Li T, de Zavalia N, Zhu L, Li J, Karthikeyan R, Alain T, Liu AC, Storch KF, Kaufman RJ, Jin VX, Amir S, Sonenberg N, Cao R 31522764
CSBN
6 Light-regulated translational control of circadian behavior by eIF4E phosphorylation. Cao R, Gkogkas CG, de Zavalia N, Blum ID, Yanagiya A, Tsukumo Y, Xu H, Lee C, Storch KF, Liu AC, Amir S, Sonenberg N 25915475
CSBN
7 mTOR signaling in VIP neurons regulates circadian clock synchrony and olfaction Liu D; Stowie A; de Zavalia N; Leise T; Pathak SS; Drewes LR; Davidson AJ; Amir S; Sonenberg N; Cao R; 29555746
CSBN

 

Title:Lab-On-A-Chip for the Development of Pro-/Anti-Angiogenic Nanomedicines to Treat Brain Diseases.
Authors:Subramaniyan Parimalam SBadilescu SSonenberg NBhat RPackirisamy M
Link:https://www.ncbi.nlm.nih.gov/pubmed/31817343?dopt=Abstract
DOI:10.3390/ijms20246126
Publication:International journal of molecular sciences
Keywords:brain angiogenesislab-on-a-chipmicrofluidicsnanomedicines
PMID:31817343 Category:Int J Mol Sci Date Added:2019-12-11
Dept Affiliation: ENCS
1 Optical-Bio Microsystems Laboratory, Micro-Nano-Bio Integration Center, Department of Mechanical and Industrial Engineering, Concordia University, Montreal, QC H3G 2W1, Canada.
2 Department of Biochemistry, McGill University, Montreal, QC H3A 1A3, Canada.
3 Department of Mechanical and Industrial Engineering, Concordia University, Montreal, QC H3G 2W1, Canada.

Description:

Lab-On-A-Chip for the Development of Pro-/Anti-Angiogenic Nanomedicines to Treat Brain Diseases.

Int J Mol Sci. 2019 Dec 05;20(24):

Authors: Subramaniyan Parimalam S, Badilescu S, Sonenberg N, Bhat R, Packirisamy M

Abstract

There is a huge demand for pro-/anti-angiogenic nanomedicines to treat conditions such as ischemic strokes, brain tumors, and neurodegenerative diseases such as Alzheimer's and Parkinson's. Nanomedicines are therapeutic particles in the size range of 10-1000 nm, where the drug is encapsulated into nano-capsules or adsorbed onto nano-scaffolds. They have good blood-brain barrier permeability, stability and shelf life, and able to rapidly target different sites in the brain. However, the relationship between the nanomedicines' physical and chemical properties and its ability to travel across the brain remains incompletely understood. The main challenge is the lack of a reliable drug testing model for brain angiogenesis. Recently, microfluidic platforms (known as "lab-on-a-chip" or LOCs) have been developed to mimic the brain micro-vasculature related events, such as vasculogenesis, angiogenesis, inflammation, etc. The LOCs are able to closely replicate the dynamic conditions of the human brain and could be reliable platforms for drug screening applications. There are still many technical difficulties in establishing uniform and reproducible conditions, mainly due to the extreme complexity of the human brain. In this paper, we review the prospective of LOCs in the development of nanomedicines for brain angiogenesis-related conditions.

PMID: 31817343 [PubMed - in process]





BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University